Gene-silencing antisense oligomers inhibit acinetobacter growth in vitro and in vivo.

BACKGROUND Peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs) are synthetic DNA/RNA analogues that silence expression of specific genes. We studied whether PPMOs targeted to essential genes in Acinetobacter lwoffii and Acinetobacter baumannii are active in vitro and in vivo. METHODS PPMOs were evaluated in vitro using minimum inhibitory concentration (MIC) and viability assays, and in vivo using murine pulmonary infection models with intranasal PPMO treatment. RESULTS MICs of PPMOs ranged from 0.1 to 64 µM (approximately 0.6-38 µg/mL). The most effective PPMO tested was (RXR)4-AcpP, which is targeted to acpP. (RXR)4-AcpP reduced viability of A. lwoffii and A. baumannii by >10(3) colony-forming units/mL at 5-8 times MIC. Mice treated with ≥0.25 mg/kg of (RXR)4-AcpP survived longer and had less inflammation and bacterial lung burden than mice treated with a scrambled-sequence PPMO or phosphate-buffered saline. Treatment could be delayed after infection and still increase survival. CONCLUSIONS PPMOs targeted to essential genes of A. lwoffii and A. baumannii were bactericidal and had MICs in a clinically relevant range. (RXR)4-AcpP increased survival of mice infected with A. lwoffii or A. baumannii, even when initial treatment was delayed after infection. PPMOs could be a viable therapeutic approach in dealing with multidrug-resistant Acinetobacter species.

[1]  H. Mori,et al.  Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection , 2006, Molecular systems biology.

[2]  P. Iversen,et al.  Gene-Specific Effects of Antisense Phosphorodiamidate Morpholino Oligomer-Peptide Conjugates on Escherichia coli and Salmonella enterica Serovar Typhimurium in Pure Culture and in Tissue Culture , 2006, Antimicrobial Agents and Chemotherapy.

[3]  S. Holland,et al.  Antisense phosphorodiamidate morpholino oligomers targeted to an essential gene inhibit Burkholderia cepacia complex. , 2010, The Journal of infectious diseases.

[4]  Vincent Schächter,et al.  A complete collection of single-gene deletion mutants of Acinetobacter baylyi ADP1 , 2008, Molecular systems biology.

[5]  D. Ottaviani,et al.  Catheter-related Bacteremia and Multidrug-resistant Acinetobacter lwoffii , 2007, Emerging infectious diseases.

[6]  P. Iversen,et al.  Antisense Phosphorodiamidate Morpholino Oligomer Length and Target Position Effects on Gene-Specific Inhibition in Escherichia coli , 2005, Antimicrobial Agents and Chemotherapy.

[7]  J. Merchant,et al.  Acinetobacter lwoffii infection and gastritis. , 2003, Microbes and infection.

[8]  J Rouviere-Yaniv [The Escherichia coli chromosome]. , 1977, Biochimie.

[9]  P. Iversen,et al.  Cationic phosphorodiamidate morpholino oligomers efficiently prevent growth of Escherichia coli in vitro and in vivo. , 2010, The Journal of antimicrobial chemotherapy.

[10]  R. Bonomo,et al.  Global Challenge of Multidrug-Resistant Acinetobacter baumannii , 2007, Antimicrobial Agents and Chemotherapy.

[11]  J. Weissenbach,et al.  Comparative Genomics of Multidrug Resistance in Acinetobacter baumannii , 2006, PLoS genetics.

[12]  P. Iversen Phosphorodiamidate Morpholino Oligomers , 2001, Antisense Drug Technology.

[13]  G. Gao,et al.  Whole-Genome Sequence of a Multidrug-Resistant Clinical Isolate of Acinetobacter lwoffii , 2011, Journal of bacteriology.

[14]  P. Iversen,et al.  Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity , 2007, Nucleic acids research.

[15]  D. Barofsky,et al.  Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. , 1996, Antisense & nucleic acid drug development.

[16]  P. Iversen,et al.  Antisense peptide-phosphorodiamidate morpholino oligomer conjugate: dose-response in mice infected with Escherichia coli. , 2006, The Journal of antimicrobial chemotherapy.

[17]  Harald Seifert,et al.  Acinetobacter baumannii: Emergence of a Successful Pathogen , 2008, Clinical Microbiology Reviews.

[18]  D. Ecker,et al.  Analysis of Antibiotic Resistance Genes in Multidrug-Resistant Acinetobacter sp. Isolates from Military and Civilian Patients Treated at the Walter Reed Army Medical Center , 2006, Antimicrobial Agents and Chemotherapy.

[19]  P. Iversen,et al.  Peptide conjugated phosphorodiamidate morpholino oligomers increase survival of mice challenged with Ames Bacillus anthracis. , 2012, Nucleic acid therapeutics.

[20]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[21]  P. Iversen,et al.  Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells. , 2007, Bioconjugate chemistry.

[22]  N. Gordon,et al.  Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. , 2010, International journal of antimicrobial agents.

[23]  J. Turton,et al.  Incidence of Acinetobacter Species Other than A. baumannii among Clinical Isolates of Acinetobacter: Evidence for Emerging Species , 2010, Journal of Clinical Microbiology.

[24]  P. Iversen,et al.  Variations in Amino Acid Composition of Antisense Peptide-Phosphorodiamidate Morpholino Oligomer Affect Potency against Escherichia coli In Vitro and In Vivo , 2008, Antimicrobial Agents and Chemotherapy.

[25]  S. Crooke Antisense Drug Technology , 2001 .

[26]  M. Adams,et al.  Comparative Genome Sequence Analysis of Multidrug-Resistant Acinetobacter baumannii , 2008, Journal of bacteriology.